Chemocentryx reported $-37216000 in EBITDA for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Ebitda Change
Abbvie ABBV:US $ 7127M 482M
Alnylam Pharmaceuticals ALNY:US $ -137.27M 45.91M
Amgen AMGN:US $ 3341M 185M
AstraZeneca AZN:LN 4187M 687M
Biogen BIIB:US $ 674.7M 20.2M
Biomarin Pharmaceutical BMRN:US $ 56.67M 96.56M
Bristol Myers Squibb BMY:US $ 5772M 404M
Chemocentryx CCXI:US $ -37.22M 1.82M
GlaxoSmithKline GSK:LN 3120M 1062M
Glaxosmithkline GSK:US $ 3120M 1062M
Johnson & Johnson JNJ:US $ 9309M 1549M
Macrogenics MGNX:US $ -63725000 8.44M
Merk MRK:US $ 6179M 492M
Mirati Therapeutics MRTX:US $ -183.59M 12.92M
Novartis NOVN:VX SF 4552M 346M
Pfizer PFE:US $ 11182M 4046M
Sarepta Therapeutics SRPT:US $ -76.16M 19.51M
Takeda 4502:JP Y 150655M 139878M
Teva Pharmaceutical TEVA:IT 1.11B 176M
YTE INCY:US $ 144.1M 9.29M